Inhibikase Therapeuticsincis A Clinical Stage Pharmaceutical Company Based In Atlantageorgiawith Additional Offices In Lexingtonmassachusettsthe Company Focuses On Developing Small Molecule Kinase Inhibitor Therapeuticsprimarily Targeting Cardiopulmonary Diseases Such As Pulmonary Arterial Hypertensionpah Its Lead Candidateikt 001Is A Prodrug Of Imatinib Mesylate Designed To Enhance Bioavailability And Tolerability For Pah Patients Inhibikase Emphasizes Translational Research To Advance Its Pipelineaddressing Unmet Medical Needs In Both Cardiopulmonary And Neurodegenerative Disordersthe Company Is Engaged In Preclinical And Clinical Research For Kinase Inhibitors And Is Actively Working On Regulatory Strategies To Progress Its Drug Candidates Through Clinical Trialsas A Nasdaq Listed Entityinhibikase Is Committed To Collaborating With Stakeholders In The Biopharmaceutical And Research Sectors
No conferences found for this company.
| Company Name | Inhibikase Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
